New hope for hearing loss? drug targets inner ear inflammation

NCT ID NCT03587701

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether anakinra (Kineret), an anti-inflammatory drug, can improve hearing in people with Meniere's disease or autoimmune inner ear disease who cannot take steroids. About 57 participants will receive daily injections of anakinra or a placebo for 42 days, followed by another 42-day period. The study measures hearing improvements and word recognition over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
anakinra (Kineret)
What this could lead to
If it works, this could offer a new treatment option for people with Meniere's or autoimmune inner ear disease who cannot use steroids, potentially improving hearing and reducing symptoms.
What could go wrong
This is a small, early phase 2 trial with only 57 participants. It may not show a clear benefit, and anakinra can cause injection site reactions or increase infection risk. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE INNER EAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwell Health, Hearing& Speech Center

    RECRUITING

    New Hyde Park, New York, 11042, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.